Xu Min, Yang Yan, Zhang Dayong, Jiang Weifeng
Department of Cardiology, The Second Affiliated Hospital of North Sichuan Medical College (Mianyang 404 Hospital), Mianyang, SiChuan, China.
Department of Cardiology, Shanghai Chest Hospital, Shanghai, China.
Acta Cardiol. 2022 Feb;77(1):14-32. doi: 10.1080/00015385.2021.1939512. Epub 2021 Jul 5.
The high power short duration (HPSD) approach was hoped to further improve the efficacy and safety in radiofrequency ablation of atrial fibrillation (AF), compared with Low power long duration (LPLD). However, the conclusion was controversial based on the previous limited data. The aim of this meta-analysis was to evaluate whether the clinical benefits of HPSD are superior to that of LPLD.
The PubMed, OVID, the Cochrane Library, and Elsevier's ScienceDirect databases were searched for clinical studies to compare HPSD and LPLD approach by simple search strings benefiting to a wider screened scope.
Fifteen trials with 3255 patients were included in this analysis. Pooled analyses suggested that HPSD was associated with a lower recurrence of atrial tachyarrhythmias (ATAs) at 1-year follow-up (OR: 0.49; 95% CI: 0.35 to 0.67, < .0001), benefitted from AF recurrence reduced (OR: 0.46; 95% CI: 0.31 to 0.67, < .0001), rather than atrial tachycardia/atrial flutter (AT/AFL), but similar at 6 months follow-up, with a decreased oesophageal thermal injury (ETI) (OR: 0.48; 95% CI: 0.30 to 0.77, = .002). Meanwhile, the HPSD approach benefitted to increase first-pass pulmonary vein isolation (FPI) (OR: 0.47; 95% CI: 0.34 to 0.64, < .00001) and decrease acute pulmonary vein re-isolation (PVR) (OR: 0.45; 95% CI: 0.35 to 0.58, < .00001), both mainly embodied in left pulmonary veins (PVs). HPSD showed a decreased procedural time (SMD: -0.95; 95% CI: -1.06 to -0.85, < .00001), ablation number for pulmonary vein isolation (PVI) (SMD: -0.41; 95% CI: -0.58 to -0.24, < .00001) and fluoroscopy time (SMD: -0.22; 95% CI: -0.32 to -0.12, < .0001), which benefits from PVI + additional ablation strategy (SMD: -0.33; 95% CI: -0.46 to -0.21, < .0001).
The HPSD approach was associated with decreasing post-ablation AF recurrence in the 1-year follow-up, ETI, acute PVR (increasing FPI correspondingly), procedural time, ablation number for PVI and fluoroscopy time, benefitted to improve clinical outcomes and procedural process with improved safety.
与低功率长时间(LPLD)方法相比,高功率短持续时间(HPSD)方法有望进一步提高房颤(AF)射频消融的疗效和安全性。然而,基于先前有限的数据,该结论存在争议。本荟萃分析的目的是评估HPSD的临床益处是否优于LPLD。
通过有助于更广泛筛选范围的简单搜索词,在PubMed、OVID、Cochrane图书馆和爱思唯尔的ScienceDirect数据库中检索比较HPSD和LPLD方法的临床研究。
本分析纳入了15项试验,共3255例患者。汇总分析表明,在1年随访时,HPSD与房性快速性心律失常(ATA)复发率较低相关(OR:0.49;95%CI:0.35至0.67,P<0.0001),受益于房颤复发减少(OR:0.46;95%CI:0.31至0.67,P<0.0001),而非房性心动过速/心房扑动(AT/AFL),但在6个月随访时相似,且食管热损伤(ETI)降低(OR:0.48;95%CI:0.30至0.77,P = 0.002)。同时,HPSD方法有助于提高首次肺静脉隔离(FPI)(OR:0.47;95%CI:0.34至0.64,P<0.00001)并降低急性肺静脉再隔离(PVR)(OR:0.45;95%CI:0.35至0.58,P<0.00001),两者主要体现在左肺静脉(PVs)。HPSD显示手术时间缩短(SMD:-0.95;95%CI:-1.06至-0.85,P<0.00001)、肺静脉隔离(PVI)消融次数减少(SMD:-0.41;95%CI:-0.58至-0.24,P<0.00001)和透视时间缩短(SMD:-0.22;95%CI:-0.32至-0.12,P<0.0001),这得益于PVI+额外消融策略(SMD:-0.33;95%CI:-0.46至-0.21,P<0.0001)。
HPSD方法与1年随访时消融后房颤复发减少、ETI、急性PVR降低(相应地增加FPI)、手术时间、PVI消融次数和透视时间减少相关,有助于改善临床结局和手术过程,并提高安全性。